|Articles|April 13, 2022
Improving Titer, Quality and Efficiency of AAV Manufacturing and Production by Optimizing Osmolality
Author(s)Advanced Instruments
Modulating osmolality in the early stages of AAV1 upstream manufacturing, can result in improved outcomes such as overall yield, quality, reduced manufacturing costs and improved efficiencies.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5